

ANZMTG Scientific Research and Annual General Meeting

Wednesday 20th November 2013 from 10:00am to 4:30pm

Russell Strong Auditorium, Princess Alexandra Hospital

Brisbane, QLD, Australia

Annual Scientific Research Meeting Agenda

Full and Associate ANZMTG members are invited to attend. Refreshments provided from 10am.

Speaker

Time

Introduction and Welcome

10:30am

ANZMTG Chairman Professor John Thompson & 2013 ASM Convenor Professor Bryan Burmeister

1. Closed and Current ANZMTG Clinical Trials; Session Chair: Bryan Burmeister

**10:30am-
11:30am**

i. ANZMTG 01.02 A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy for regional control in patients with completely resected macroscopic nodal metastatic melanoma	<i>Michael Henderson</i>	10 minutes presentation & 5 minutes discussion per protocol
a. Study Chairmans' perspective on the final results and publication		
b. New sub studies and future directions		
ii. ANZMTG 01.07 Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial (WBRTMel)	<i>Gerald Fogarty</i>	
a. Progress Update, new sub studies and future directions		
iii. ANZMTG 01.09 A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2)	<i>Matthew Foote</i>	
iv. ANZMTG 02.09 Vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial (Mel-D)	<i>Robyn Saw</i>	
v. ANZMTG 01.11 Phase I Study of Safety and Immune Effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral T Cells in Patients with Metastatic Melanoma (CARPETS)	<i>Michael Brown</i>	(will not be presented, refer to trial summary)
vi. EORTC QOL Melanoma Module (MelMod)	<i>Julie Winstanley</i>	(will not be presented, refer to trial summary)

2. ANZMTG Approved Trials In Development; Session Chair: Bryan Burmeister

11:30am-12:30pm

i. ANZMTG 01.12 Inguinal or Ilio-inguinal Lymph Node Dissection for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET / CT Scan-A randomised phase III trial (EAGLE FM)	<i>Chris Allan</i>	10 minutes presentation & 5 minutes discussion per protocol
ii. ANZMTG 02.12 A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails (RADICAL)	<i>Gerald Fogarty</i>	
iii. ANZMTG 03.12 Melanoma Excision Margins Trial (MelMarT)	<i>Michael Henderson</i>	
iv. ANZMTG 04.12 Radiotherapy followed by selective nodal dissection for high volume regional melanoma (REFORM)	<i>Matthew Foote</i>	

Lunch

**12:30pm-
1:30pm**

Full ANZMTG members invited to attend the ANZMTG AGM

Afternoon Sessions	Speaker	Time
3. New Research Proposals; Session Chair: Bryan Burmeister		
ANZMTG lead initiatives		
i. NRP 01.13 112195: A randomised controlled trial with embedded biological discovery and validation leading to the rational treatment of people with the rare virus-associated aggressive skin malignancy, Merkel Cell Carcinoma (MCC)	<i>Gerald Fogarty</i>	10 minutes presentation & 5 minutes discussion per protocol
ii. NRP 02.13 A randomised phase II study of immunotherapy with DPCP treated autologous melanoma vaccines	<i>Peter Hersey</i>	
iii. NRP 03.13 Prospective Randomized Trial Comparing Complex Decongestive Therapy (CDT) Alone vs CDT and Vascularized Lymph Node Transfer vs CDT and Adipofascial Free Flap in Treatment of Secondary Lymphoedema	<i>Sydney Ch'ng</i>	
iv. NRP 04.13 Large multicentre observational study to monitor and improve routine imaging of volatile naevus for patients with advanced melanoma	<i>Peter Soyer</i>	
Collaborative group initiatives		
v. NRP 05.13 ANZMTG / POCOG collaboration: A randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease.	<i>Anne Cust</i>	
<i>Discussion of New Proposals – Q&A</i>	<i>Bryan Burmeister</i>	2:45-3:00pm
Afternoon tea		
4. Melanoma Research Presentations; Session Chair: Bryan Burmeister		
Consumer engagement – Australian Melanoma Consumer Alliance Annual Update on recent milestones and achievements	<i>Paul White</i>	3:00 -3:15pm
Recent advances in the management of Melanoma treatment		3:15-3:45pm
i. Surgery Update	<i>John Thompson</i>	
ii. Update on clinical trials for Advanced Melanoma	<i>Victoria Atkinson</i>	
What is health economics and how will it influence trial design for melanoma protocols and how will it guide health policy, pricing and access to new treatments?	<i>Marion Haas</i>	3:45 -4:00pm
Concluding Remarks; Session Chair: Bryan Burmeister		4:00pm-4:30pm
Meeting close		

ANZMTG Annual General Meeting 2013

Full ANZMTG members are welcome to attend the AGM, commences at 12:40pm

Agenda	Speaker	Attachments
1 Greetings and Apologies	<i>Chairman, Prof John Thompson</i>	
2 Review and Approve Minutes of Previous Meeting	<i>John Thompson</i>	2012 AGM Minutes (1)
3 Overview of the 2013-2016 Cancer Australia grant and Strategic Direction	<i>Libby Paton</i>	Strategic Plan – Summary (2)
4 Chairman's report	<i>John Thompson</i>	Chairman's report (3)
5 Finance report	<i>Libby Paton</i>	Financial statement 12/13 (4)
6 Operations report	<i>Libby Paton</i>	ANZMTG Clinical Trials Summary (5) ANZMTG Membership & Activities (6) ANZMTG Publications Summary (7)
7 Executive Committee Membership; Terms of Reference and Nomination Process	<i>John Thompson</i>	
8 Other business	All	
9 Meeting Close at 1pm		